News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,574 Results
Type
Article (14894)
Company Profile (299)
Press Release (266375)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79834)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50696)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145071)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6030)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3128)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43668)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4320)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (214)
Earnings (31643)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51661)
Executive appointments (621)
FDA (7583)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (329)
Peanut (43)
People (26650)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15474)
Phase 2 (20289)
Phase 3 (12820)
Pipeline (3246)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1447)
Recruiting (12)
Regulatory (9892)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (12)
Last 7 days (344)
Last 30 days (1126)
Last 365 days (17808)
2026 (1663)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18250)
Australia (3111)
California (7074)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39157)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1762)
North Carolina (827)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (905)
United States (23331)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,574 Results for "renagade therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
ReNAgade Therapeutics announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem.
April 26, 2024
·
3 min read
Deals
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
Orna Therapeutics today announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
May 23, 2024
·
4 min read
Genetown
ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
April 22, 2024
·
3 min read
Genetown
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
ReNAgade Therapeutics today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.
February 22, 2024
·
1 min read
Business
ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023.
December 5, 2023
·
2 min read
Deals
Orna Buys Competing RNA Biotech ReNAgade After Series A Financing
Orna Therapeutics announced Thursday it is acquiring ReNAgade Therapeutics, which launched in May 2023 with $300 million in Series A financing and is on BioSpace’s NextGen Class of 2024 startups to watch this year.
May 23, 2024
·
2 min read
·
Tyler Patchen
Business
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
ReNAgade Therapeutics today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
February 27, 2024
·
2 min read
Business
ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
ReNAgade Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
September 12, 2023
·
2 min read
Genetown
ReNAgade Therapeutics Named to the 2023 Endpoints 11
ReNAgade Therapeutics today announced that it has been named as one of the Endpoints 11 companies of 2023, awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.
September 21, 2023
·
2 min read
Business
ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.
January 4, 2024
·
1 min read
1 of 28,158
Next
